Trade

with

Novogen Ltd
(NASDAQ: NVGN)
AdChoices
2.88
-0.05
-1.71%
After Hours :
-
-
-

Open

3.03

Previous Close

2.93

Volume (Avg)

18.49k (12.09k)

Day's Range

2.86-3.03

52Wk Range

2.68-6.84

Market Cap.

19.36M

Dividend Rate ( Yield )

-

Beta

0.89

Shares Outstanding

6.74M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Drug Manufacturers – Major
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 1.52M

    • Net Income

    • -904.27k

    • Market Cap.

    • 19.36M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -398.72

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.89

    • Forward P/E

    • -

    • Price/Sales

    • 2.45

    • Price/Book Value

    • 4.62

    • Price/Cash flow

    • -0.80

      • EBITDA

      • -912.17k

      • Return on Capital %

      • -70.06

      • Return on Equity %

      • -118.85

      • Return on Assets %

      • -70.06

      • Book Value/Share

      • 0.55

      • Shares Outstanding

      • 6.74M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • -

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -15.20

          • 0.89

          • Net Income

            YTD/YTD (last year)

          • -

          • 7.80

          • Net Income

            Q/Q (last year)

          • -

          • 4.50

          • Sales (Revenue)

            5-Year Annual Average

          • -33.47

          • 6.10

          • Net Income

            5-Year Annual Average

          • -

          • 3.73

          • Dividends

            5-Year Annual Average

          • -

          • 2.17

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 69.92

            • Pre-Tax Margin

            • -399.97

            • 21.84

            • Net Profit Margin

            • -398.72

            • 18.37

            • Average Gross Margin

              5-Year Annual Average

            • 91.00

            • 71.90

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -270.30

            • 21.92

            • Average Net Profit Margin

              5-Year Annual Average

            • -124.30

            • 903.40B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.32

              • Current Ratio

              • 1.60

              • 1.92

              • Quick Ratio

              • 1.60

              • 1.31

              • Interest Coverage

              • -5.86

              • 17.64

              • Leverage Ratio

              • 1.84

              • 2.03

              • Book Value/Share

              • 0.62

              • 14.62

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -0.59

                • 22.99

                • P/E Ratio 5-Year High

                • -2.23

                • 193.96

                • P/E Ratio 5-Year Low

                • -0.10

                • 87.26

                • Price/Sales Ratio

                • 2.35

                • 3.84

                • Price/Book Value

                • 4.44

                • 3.83

                • Price/Cash Flow Ratio

                • -0.80

                • 14.51

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -118.85

                        (-43.60)

                      • 17.42

                        (18.66)

                      • Return on Assets %

                        (5-Year Average)

                      • -70.06

                        (-26.50)

                      • 8.45

                        (8.77)

                      • Return on Capital %

                        (5-Year Average)

                      • -52.71

                        (-42.70)

                      • 12.41

                        (13.18)

                      • Income/Employee

                      • -

                      • 90.07k

                      • Inventory Turnover

                      • -

                      • 2.46

                      • Asset Turnover

                      • 0.18

                      • 0.46

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -1.21M
                      Operating Margin
                      -79.54
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -0.80
                      Ownership

                      Institutional Ownership

                      0.22%

                      Top 10 Institutions

                      0.21%

                      Mutual Fund Ownership

                      -

                      Float

                      -

                      5% / Insider Ownership

                      0.29%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Columbia Management Company

                      •  

                        3,000

                      • 0.00%

                      • 0.04

                      • Morgan Stanley Smith Barney LLC

                      •  

                        2,300

                      • -45.83%

                      • 0.03

                      • Merrill Lynch & Co Inc

                      •  

                        1,046

                      • 0.00%

                      • 0.02

                      • UBS Securities LLC

                      •  

                        927

                      • +32.62%

                      • 0.01

                      • UBS Financial Services Inc.

                      •  

                        500

                      • 0.00%

                      • 0.01

                      • Creative Planning, Inc.

                      •  

                        200

                      • 0.00%

                      • 0.00

                      • Columbia Mangmt Investment Advisers, LLC

                      •  

                        78

                      • +160.00%

                      • 0.00

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Drug Manufacturers – Major

                      Type

                      Slow Growth

                      Style

                      Small Growth

                      Novogen Ltd was incorporated in March 1994 under the jurisdiction of the laws of New South Wales, Australia. The Company is engaged in pharmaceutical drug development. It develops single drug capable of killing both the dominant differentiated cells in a cancer as well as the undifferentiated cancer stem cells at a therapeutic dose. The Company's inaugural drug candidate CS-6 belongs to a new class of drug candidates known as Mitochondrial Electron Transfer Inhibitors that work by depriving the cancer cell of its main energy source. The Company’s competitors include pharmaceutical companies and biotechnology companies, as well as universities and public and private research institutions. The activities of the Company are subject to numerous Australian laws and regulations.

                      Key People

                      Daniel P. Gold,PhD

                      CEO, Subsidiary/President, Subsidiary

                      Dr. Graham E. Kelly

                      CEO/Chairman of the Board/Director

                      Mr. Thomas Zech

                      CFO, Subsidiary

                      Mr. Mark G. Hinze

                      CFO, Subsidiary

                      Mr. Steven Coffey

                      CFO/Director

                      • Novogen Ltd

                      • 16-20 Edgeworth David Avenue

                      • Sydney, NSW 2077

                      • AUS.Map

                      • Phone: +61 294760344

                      • Fax: +61 294760388

                      • novogen.com

                      Incorporated

                      1994

                      Employees

                      5

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: